CSIMarket
 
Halozyme Therapeutics Inc   (NASDAQ: HALO)
Other Ticker:  
 
 

Halozyme Therapeutics Inc's Customers Performance

HALO


 
 
HALO's Source of Revenues During the corresponding time, Halozyme Therapeutics Inc recorded a revenue increase by 35.22 % year on year, sequentially revenue fell by -11.12 %. While revenue at the Halozyme Therapeutics Inc 's corporate clients

List of HALO Customers




for the same period Halozyme Therapeutics Inc recorded revenue increase by 35.22 % year on year, sequentially revenue fell by -11.12 %.

List of HALO Customers

Halozyme Therapeutics Inc's Business Units
Royalties    63.5 % of total Revenue
Product sales net    29.46 % of total Revenue
Proprietary product sales    13.72 % of total Revenue
Bulk rHuPH20 sales    10.2 % of total Revenue
Device partnered product sales    5.54 % of total Revenue
Revenues under collaborative agreements    7.03 % of total Revenue
Upfront license and target nomination fees    0.08 % of total Revenue
Sales-based milestones    5.66 % of total Revenue
Device licensing and development revenue    1.29 % of total Revenue
Other collaborators    61.69 % of total Revenue
License Fees and Event-Based    69.17 % of total Revenue
Product    58.22 % of total Revenue






Halozyme Therapeutics Inc's Comment on Sales, Marketing and Customers
















HALO's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Halozyme Therapeutics Inc 6,907.16 1,084.31 485.36 3,011
SUBTOTAL 0.00 0.00 0.00 -


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright � 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com